We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sangamo Announces Expansion of Research Collaboration Agreement with Pfizer

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sangamo Announces Expansion of Research Collaboration Agreement with Pfizer"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Sangamo BioSciences, Inc. has announced that it has entered into a second agreement with Pfizer Inc that expands the scope of existing research collaboration in the field of enhanced protein production.

Under the terms of the agreement, Pfizer will fund further research at Sangamo and Sangamo will use its zinc finger DNA-binding protein (ZFP) technology to develop additional cell lines for enhanced protein production.

"Over the past year we have enjoyed a very productive collaboration with Pfizer, the world's leading research-based pharmaceutical company," said Edward Lanphier, Sangamo's president and chief executive officer.

"We believe that the expansion of this agreement is evidence of our successful development and application of this technology to facilitate the generation of improved production cell lines with altered traits."

By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP transcription factors (ZFP TFs™) that can control gene expression and consequently, cell function.

Sangamo is also developing sequence-specific ZFP nucleases (ZFNs™) for targeted gene correction, gene disruption and gene insertion.